WallStSmart

Insmed Inc (INSM)vsThird Harmonic Bio Inc. (THRD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

THRD leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

THRD

Avoid

32

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.5
Piotroski: 2/9Altman Z: 17.98

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

THRD3 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
17.9810/10

Safe zone — low bankruptcy risk

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

THRD4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$242.79M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : THRD

The strongest argument for THRD centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : THRD

The primary concerns for THRD are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while THRD is a value play — different risk/reward profiles.

THRD carries more volatility with a beta of 2.13 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

THRD generates stronger free cash flow (-13M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Third Harmonic Bio Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Third Harmonic Bio Inc. is a pioneering biotechnology firm focused on creating groundbreaking therapies for severe immunology and inflammation-related disorders. Leveraging a proprietary genetic engineering platform, the company is advancing an innovative pipeline of drug candidates designed to meet critical unmet medical needs in this therapeutic area. With a strong dedication to scientific rigor and enhancing patient outcomes, Third Harmonic Bio is well-positioned to make a significant impact on the biopharmaceutical sector and improve the quality of care for patients confronting substantial health challenges.

Want to dig deeper into these stocks?